Celcuity Inc. (CELC)
| Market Cap | 4.26B +947.3% |
| Revenue (ttm) | n/a |
| Net Income | -192.89M |
| EPS | -3.89 |
| Shares Out | 48.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,437,721 |
| Open | 88.00 |
| Previous Close | 88.28 |
| Day's Range | 86.00 - 91.00 |
| 52-Week Range | 11.28 - 151.02 |
| Beta | 0.12 |
| Analysts | Strong Buy |
| Price Target | 161.09 (+84.25%) |
| Earnings Date | May 14, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $161.09, which is an increase of 84.25% from the latest price.
News
Celcuity Slides: FY 2026
Celcuity has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
Celcuity Transcript: Jefferies Global Healthcare Conference 2026
Gedatolisib demonstrated strong efficacy in phase III breast cancer trials, with both doublet and triplet regimens doubling progression-free survival versus control. Regulatory review is progressing, commercialization plans are advanced, and the drug is positioned as a potential new standard of care with a robust cash runway through 2029.
Celcuity prices $500M convertible senior note offering
Celcuity (CELC) announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032. The aggregate principal am...
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for t...
Celcuity price target lowered to $171 from $189 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Celcuity (CELC) to $171 from $189 and keeps a Buy rating on the shares following ASCO data from VIKTORIA-1 study 2 evaluating gedatolisib…
Celcuity price target lowered to $166 from $183 at Wells Fargo
Wells Fargo analyst Eva Fortea Verdejo lowered the firm’s price target on Celcuity (CELC) to $166 from $183 and keeps an Overweight rating on the shares. While stock weakness reflects…
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for t...
Celcuity price target lowered to $145 from $185 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Celcuity (CELC) to $145 from $185 and keeps a Buy rating on the shares after the company presented results from the PIK3CA-mutant…
Celcuity plunges after experimental breast cancer treatment data disappoints
Celcuity shares slumped 25% , set for their biggest one-day decline, on Tuesday after its experimental breast cancer treatment extended the period of time a patient lives without the disease worseni...
Celcuity reports efficacy, safety data from PIK3CA mutant cohort of VIKTORIA-1
Celcuity (CELC) announced detailed efficacy and safety results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in...
Celcuity's Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
MINNEAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple soli...
Celcuity Transcript: Study result
The VIKTORIA-1 phase III trial showed gedatolisib-based regimens significantly improved progression-free survival and objective response rates versus standard therapy in HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, with favorable safety and low discontinuation rates. Gedatolisib may become a new standard of care for both PIK3CA wild-type and mutant populations.
Celcuity Press release: Study result
Celcuity issued a press release on June 2, 2026, disclosing material business information to investors.
Celcuity Slides: Study result
Celcuity has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
MINNEAPOLIS, June 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid...
Celcuity To Participate in Upcoming Investor Conferences
MINNEAPOLIS, May 28, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid ...
Celcuity price target raised to $185 from $165 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $185 from $165 and keeps a Buy rating on the shares. With the announcement of Study…
Celcuity price target raised to $175 from $150 at Stifel
Stifel raised the firm’s price target on Celcuity (CELC) to $175 from $150 and keeps a Buy rating on the shares.
Celcuity price target raised to $183 from $150 at Wells Fargo
Wells Fargo raised the firm’s price target on Celcuity (CELC) to $183 from $150 and keeps an Overweight rating on the shares. The firm thought the company’s recent updates were…
Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year
Net cash used in operating activities for the first quarter of 2026 was $55.1M, compared to $35.9M for the prior year period. “With positive results in both cohorts of the…
Celcuity Earnings Call Transcript: Q1 2026
Q1 2026 saw positive phase III results for gedatolisib in advanced breast cancer, expansion of clinical programs, and full commercial launch readiness. Net loss increased year-over-year, but cash reserves are expected to fund operations through 2027.
Celcuity Earnings release: Q1 2026
Celcuity released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q1 2026
Celcuity has published its Q1 2026 quarterly earnings report on May 14, 2026.